Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China

Abstract The objective of this study was to evaluate the efficacy and safety of propranolol hydrochloride tablets and oral solution in neonates with severe IHs. A retrospective cohort study included 184 consecutive neonates diagnosed with severe IHs and treated with propranolol from January 2016 to...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhiping Wu, Yun Zou, Hua Yuan, Ronghua Fu, Pingliang Jin
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-024-84653-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841559668572291072
author Zhiping Wu
Yun Zou
Hua Yuan
Ronghua Fu
Pingliang Jin
author_facet Zhiping Wu
Yun Zou
Hua Yuan
Ronghua Fu
Pingliang Jin
author_sort Zhiping Wu
collection DOAJ
description Abstract The objective of this study was to evaluate the efficacy and safety of propranolol hydrochloride tablets and oral solution in neonates with severe IHs. A retrospective cohort study included 184 consecutive neonates diagnosed with severe IHs and treated with propranolol from January 2016 to June 2023. Of these, 126 patients received propranolol tablets, and 58 received propranolol oral solution. The primary outcome assessed the treatment response post-discontinuation of propranolol, while the key secondary outcome measured changes in the hemangioma activity score (HAS). Out of 184 participants, 138 (75.5%) were female. The mean age at treatment initiation was 16 days (range: 10–22) for the tablet group and 14 days (range: 8–24) for the oral solution group. Following treatment, effective response rates were 74.6% in the tablet group and 87.9% in the oral solution group (P = 0.04). Improvement in the HAS was 63.95% for the tablet group and 65.57% for the oral solution group (P = 0.35). Adverse reactions included diarrhea in 29.0% of tablet group and 12.9% of oral solution group (P = 0.01), and sleep disturbances in 20.6% of tablet group and 8.6% of oral solution group (P = 0.04). In terms of sequelae, telangiectasia occurred in 34.9% of tablet group and 17.2% of oral solution group (P = 0.01). Propranolol oral solution showed superior efficacy and safety compared to tablets in treating neonates with severe IHs, suggesting it should be prioritized as the preferred treatment option for this vulnerable population.
format Article
id doaj-art-7281d58a2bcd46108e0220c8cdecf879
institution Kabale University
issn 2045-2322
language English
publishDate 2025-01-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-7281d58a2bcd46108e0220c8cdecf8792025-01-05T12:16:11ZengNature PortfolioScientific Reports2045-23222025-01-011511810.1038/s41598-024-84653-0Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in ChinaZhiping Wu0Yun Zou1Hua Yuan2Ronghua Fu3Pingliang Jin4Department of Plastic Surgery, Jiangxi Provincial Children’s HospitalDepartment of Plastic Surgery, Jiangxi Provincial Children’s HospitalDepartment of Plastic Surgery, Jiangxi Provincial Children’s HospitalDepartment of Plastic Surgery, Jiangxi Provincial Children’s HospitalDepartment of Plastic Surgery, Jiangxi Provincial Children’s HospitalAbstract The objective of this study was to evaluate the efficacy and safety of propranolol hydrochloride tablets and oral solution in neonates with severe IHs. A retrospective cohort study included 184 consecutive neonates diagnosed with severe IHs and treated with propranolol from January 2016 to June 2023. Of these, 126 patients received propranolol tablets, and 58 received propranolol oral solution. The primary outcome assessed the treatment response post-discontinuation of propranolol, while the key secondary outcome measured changes in the hemangioma activity score (HAS). Out of 184 participants, 138 (75.5%) were female. The mean age at treatment initiation was 16 days (range: 10–22) for the tablet group and 14 days (range: 8–24) for the oral solution group. Following treatment, effective response rates were 74.6% in the tablet group and 87.9% in the oral solution group (P = 0.04). Improvement in the HAS was 63.95% for the tablet group and 65.57% for the oral solution group (P = 0.35). Adverse reactions included diarrhea in 29.0% of tablet group and 12.9% of oral solution group (P = 0.01), and sleep disturbances in 20.6% of tablet group and 8.6% of oral solution group (P = 0.04). In terms of sequelae, telangiectasia occurred in 34.9% of tablet group and 17.2% of oral solution group (P = 0.01). Propranolol oral solution showed superior efficacy and safety compared to tablets in treating neonates with severe IHs, suggesting it should be prioritized as the preferred treatment option for this vulnerable population.https://doi.org/10.1038/s41598-024-84653-0Infantile hemangiomasNeonatesPropranolol hydrochloride oral solutionPropranolol hydrochloride tablets
spellingShingle Zhiping Wu
Yun Zou
Hua Yuan
Ronghua Fu
Pingliang Jin
Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China
Scientific Reports
Infantile hemangiomas
Neonates
Propranolol hydrochloride oral solution
Propranolol hydrochloride tablets
title Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China
title_full Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China
title_fullStr Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China
title_full_unstemmed Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China
title_short Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China
title_sort efficacy and safety of propranolol tablets vs oral solution in neonates with severe infantile hemangiomas a retrospective study in china
topic Infantile hemangiomas
Neonates
Propranolol hydrochloride oral solution
Propranolol hydrochloride tablets
url https://doi.org/10.1038/s41598-024-84653-0
work_keys_str_mv AT zhipingwu efficacyandsafetyofpropranololtabletsvsoralsolutioninneonateswithsevereinfantilehemangiomasaretrospectivestudyinchina
AT yunzou efficacyandsafetyofpropranololtabletsvsoralsolutioninneonateswithsevereinfantilehemangiomasaretrospectivestudyinchina
AT huayuan efficacyandsafetyofpropranololtabletsvsoralsolutioninneonateswithsevereinfantilehemangiomasaretrospectivestudyinchina
AT ronghuafu efficacyandsafetyofpropranololtabletsvsoralsolutioninneonateswithsevereinfantilehemangiomasaretrospectivestudyinchina
AT pingliangjin efficacyandsafetyofpropranololtabletsvsoralsolutioninneonateswithsevereinfantilehemangiomasaretrospectivestudyinchina